Six-Month Treatment With Alendronate in Acute Charcot Neuroarthropathy

Pitocco, Dario; Ruotolo, Valeria; Caputo, Salvatore; Mancini, L; Collina, Chiara M.; Manto, Andrea; Caradonna, Paolo; Ghirlanda, Giovanni

doi:10.2337/diacare.28.5.1214

Cited by 154 publications

(99 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median time to resolution in this survey was longer than that reported in single-centre cohorts [11][12][13][14], one possible explanation being that we had predefined resolution as the patient being ambulant in normal or orthotic footwear. As the measuring, ordering, manufacture, fitting and 'breaking-in' of such footwear can take several weeks, it is possible that the actual time to resolution was rather shorter than reported here.…”

Section: Discussionmentioning

confidence: 45%

Audit of acute Charcot’s disease in the UK: the CDUK study

et al. 2011

View full text Add to dashboard Cite

Aims/hypothesis We studied factors associated with the development and resolution of acute Charcot foot using a web-based observational study. centres. Of these, 36% of patients recalled an episode of relevant trauma in the preceding 6 months, while 12% had had surgery to the affected foot. In 101 (35%) cases, ulceration was present at registration and 20% of these had osteomyelitis. Non-removable off-loading devices were used at presentation in 35.4% of cases, with removable off-loading used in 50%. Data on resolution were available for 219 patients. The median time to resolution was 9 months in patients whose initial management included the use of non-removable off-loading, compared with 12 months in the remainder (p=0.001). Bisphosphonates were administered intravenously in 25.4% and orally in 19.4% of cases. The median time to resolution in patients who received bisphosphonates was 12 months and was longer than in those who did not (10 months, p=0.005). Conclusions/interpretation The median time to resolution was longer than in earlier series. Although limited by being observational and non-randomised, these data suggest that the use of non-removable off-loading at presentation may shorten the time to resolution. They provide no evidence to indicate that the use of bisphosphonates is beneficial.

show abstract

Section: Discussionmentioning

confidence: 45%

Audit of acute Charcot’s disease in the UK: the CDUK study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…A clinical improvement was observed and, 1CTP and urinary hydroxyproline levels, as indicators of bone resorption, showed a significant decrease in the treated group after treatment (Pitocco et al, 2005).…”

Section: Imaging and Biochemical Markers Of Bone Turnover After Medicmentioning

confidence: 83%

“…The improvement with bisphosphonates appears to be sooner compared to patients with conventional therapy www.intechopen.com (immobilization) (Anderson et al, 2004). Most studies use pamidronate, although alendronate has been demonstrated to be useful in one study (Pitocco et al, 2005). The optimal treatment regimen of pamidronate remains to be defined.…”

Section: Imaging and Biochemical Markers Of Bone Turnover After Medicmentioning

confidence: 99%

Pamidronate Treatment in Charcot Neuro-Osteoarthropathy: Change in Biochemical Markers of Bone Turnover and Radiographic Outcome After Treatment

Vázquez¹,

Moreno²,

Larrosa³

2012

Insights and Perspectives in Rheumatology

View full text Add to dashboard Cite

“…It is important to note that these subjects were receiving parenteral bisphosphonates for malignancy related causes and more frequently. In a randomized control pilot study of the effect of oral alendronate once a week on acute Charcot neuropathy, the authors noted that there was a significant reduction of ICTP and hydroxyprolin, markers indicative of bone resorption [29]. Although the purpose of the study was to evaluate the benefit of bisphosphonate treatment on Charcot's disease, it also demonstrated an improvement in the bone turnover markers in subjects with diabetes on oral bisphosphonates.…”

Section: Discussionmentioning

confidence: 99%

Oral bisphosphonates improve the bone mineral density in men with diabetes with or without thiazolidinediones

Yaturu¹,

Davis²

2011

JDM

View full text Add to dashboard Cite

Background: Osteoporosis and type 2 diabetes mellitus (DM) are two of the most common chronic conditions and represent major public health burdens. Epidemiological and observational studies indicate that thiazolidinedione (TZD) therapy with rosiglitazone and pioglitazone is associated with an increased risk of fractures and decreased bone mineral density (BMD). To our knowledge, no data are available to evaluate bisphosphonate therapy in TZD treated patients. Aim: The aim of this study was to investigate the benefit of bisphosphonates to improve changes in BMD associated with the use of TZDs in subjects with DM. Methods: In a cross-sectional, observational study using a retrospective review of electronic mfedical records, the changes in BMD were compared in subjects with type 2 DM. The study subjects were divided into four groups. First group is with DM receiving both TZDs and BPs; second group TZD use only; third group receiving neither TZDs nor BPs and the fourth only BPs. The study compared the annual percent changes in BMD between the groups. Results: Decreased BMD was noted in subjects with DM on TZDs. Bisphosphonate use improved BMD in subjects with DM on TZDs. BMD improved in subjects with DM in those not receiving TZDs also. Conclusion: We conclude that concomitant treatment with bisphosphonates improves BMD in subjects with diabetes and on TZDs.

show abstract

Six-Month Treatment With Alendronate in Acute Charcot Neuroarthropathy

Cited by 154 publications

References 16 publications

Audit of acute Charcot’s disease in the UK: the CDUK study

Audit of acute Charcot’s disease in the UK: the CDUK study

Pamidronate Treatment in Charcot Neuro-Osteoarthropathy: Change in Biochemical Markers of Bone Turnover and Radiographic Outcome After Treatment

Oral bisphosphonates improve the bone mineral density in men with diabetes with or without thiazolidinediones

Contact Info

Product

Resources

About